2026 年第 1 期 第 21 卷

丁苯酞氯化钠注射液联合依达拉奉右莰醇注射用浓溶液对急性脑梗死患者神经功能和脑血流的影响

Effects of butylphthalide sodium chloride injection combined with edaravone dexborneol concentrated solution for injection on neurological function and cerebral blood flow in patients with acute cerebral infarction

作者：刘海燕王丹陈晗

英文作者：Liu Haiyan Wang Dan Chen Han

单位：江苏省南京市中心医院神经内科，南京210018

英文单位：Department of Neurology Nanjing Central Hospital Jiangsu Province Nanjing 210018 China

关键词：急性脑梗死；丁苯酞氯化钠；依达拉奉右莰醇；神经功能；脑血流

英文关键词：Acutecerebralinfarction;Butylphthalidesodiumchloride;Edaravonedexborneol;Neurologicalfunction;Cerebralbloodflow

• 摘要：

• 目的 探究丁苯酞氯化钠注射液联合依达拉奉右莰醇注射用浓溶液对急性脑梗死（ACI）患者的神经功能和脑血流的影响。方法 选取江苏省南京市中心医院2022年6月至2024年12月收治的ACI患者89例，按照随机数字表法分为对照组（44例）和观察组（45例）。在常规治疗基础上，对照组予以丁苯酞氯化钠注射液治疗，观察组予以丁苯酞氯化钠注射液+依达拉奉右莰醇注射用浓溶液治疗，2组均治疗2周。比较2组治疗前后脑血流状态、血清指标［血清中枢神经特异性蛋白（S-100β）、C反应蛋白（CRP）］水平，评估治疗后1年内预后［改良Rankin量表（mRS）评分］情况，比较2组用药后不良反应发生情况。结果 治疗后，2组大脑中动脉、椎动脉和基底动脉平均血流速度均高于治疗前，且观察组均高于对照组（均P<0.05）。治疗后，2组血清S-100β、CRP水平均低于治疗前（均P＜0.05），且观察组均低于对照组［（0.49±0.14）μg/L比（0.65±0.17）μg/L、（0.81±0.25）mg/L比（0.94±0.22）mg/L］（均P＜0.05）。治疗后，2组mRS评分呈逐步下降趋势，且观察组治疗后3、6个月及治疗后1年mRS评分均低于对照组（均P<0.05）。2组不良反应发生率比较差异无统计学意义（P＞0.05）。结论 丁苯酞氯化钠与依达拉奉右莰醇联合治疗能够有效促进ACI患者神经功能的恢复，加快脑血流速度，并显著降低炎症指标水平。

• Objective To investigate the effects of butylphthalide sodium chloride injection combined with edaravone dexborneol concentrated solution for injection on neurological function and cerebral blood flow in patients with acute cerebral infarction (ACI). Methods A total of 89 ACI patients admitted to Nanjing Central Hospital, Jiangsu Province from June 2022 to December 2024 were selected and divided into a control group (44 cases) and an observation group (45 cases) according to the random number table method. On the basis of conventional treatment, the control group was treated with butylphthalide sodium chloride injection, and the observation group was treated with butylphthalide sodium chloride injection plus edaravone dexborneol concentrated solution for injection, with both groups receiving treatment for 2 weeks. The cerebral blood flow status and serum indexes ［serum central nervous system-specific protein (S-100β), C-reactive protein (CRP)］ levels before and after treatment were compared between the two groups, the prognosis ［modified Rankin Scale (mRS) score］ within 1 year after treatment was evaluated, and the incidence of adverse reactions after medication was compared between the two groups. Results After treatment, the mean blood flow velocities of the middle cerebral artery, vertebral artery and basilar artery in both groups were higher than those before treatment, and those in the observation group were higher than those in the control group (all P<0.05). After treatment, the serum levels of S-100β and CRP in both groups were lower than those before treatment (all P<0.05), and those in the observation group were lower than those in the control group ［(0.49±0.14)μg/L vs (0.65±0.17)μg/L, (0.81±0.25)mg/L vs (0.94±0.22)mg/L］(all P<0.05). After treatment, the mRS scores of both groups showed a gradual downward trend, and the mRS scores of the observation group at 3 months, 6 months and 1 year after treatment were lower than those of the control group (all P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion  The combined treatment of butylphthalide sodium chloride and edaravone dexborneol can effectively promote the recovery of neurological function, accelerate the improvement of cerebral blood flow velocity, significantly reduce the levels of inflammatory indexes in ACI patients.